ImmunoPrecise Antibodies (NASDAQ:IPA) (NASDAQ: IPA) is a contract research organization focused on the discovery, development and optimization of antibodies. The company offers a full suite of services that span early‐stage discovery through to candidate selection, providing clients with monoclonal and polyclonal antibody solutions, custom immunochemistry assay development, and cell line engineering support. Leveraging multiple discovery platforms, ImmunoPrecise Antibodies tailors its approach to meet the unique requirements of therapeutic, diagnostic and research applications.
The company’s service offerings include hybridoma generation, phage display, single B cell screening and recombinant antibody engineering. These technologies enable rapid identification and humanization of high‐affinity antibody candidates. In addition, ImmunoPrecise Antibodies provides cell line development and protein expression support, helping clients to advance their molecules through scalable biomanufacturing processes and analytical characterization.
Headquartered in Victoria, British Columbia, ImmunoPrecise Antibodies maintains laboratories in North America, Europe and Asia Pacific to serve a global client base that ranges from emerging biotech firms to large pharmaceutical companies. Since its inception, the company has expanded its footprint through targeted facility investments, supporting projects across immuno‐oncology, autoimmunity, neuroscience and infectious disease research.
Under the leadership of President and CEO Dr. Paul R. Lem, PhD, ImmunoPrecise Antibodies has pursued strategic growth through both organic development and selective asset acquisitions. The management team combines expertise in antibody science, drug development and business operations, positioning the company to address evolving client needs in the rapidly advancing field of biotherapeutics.
